Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer (Q43654264)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer |
scientific article |
Statements
1 reference
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer (English)
1 reference
Alberto Muñoz
Carlos García-Girón
Vicente Alonso
Rosario Dueñas
Luis Cirera
Fernando Rivera
Esther Falcó
Iñaki Alvarez Bustos
1 January 2013
1 reference